Compare Cigna Corp (CI) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Nutanix Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Nutanix Inc trades at $64.25 (market cap $17.42B). The key difference: Cigna Corp is far larger — about 4.2× Nutanix Inc's market cap, and Cigna Corp pays a 2.24% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals.
| CI | NTNX | |
|---|---|---|
Market Cap | $73.56B | $17.42B |
Sector | Health | Technology |
52-Week High | $311.00 | $81.12 |
52-Week Low | $244.41 | $34.41 |
Enterprise Value | $98.27B | $16.94B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
Nutanix (NTNX) trades at $62.67, up 4.24% today, with strong technical and fundamental momentum. The stock is near its 52-week high, supported by bullish moving averages and consistent earnings beats. Revenue growth is robust, with 2026 revenue projected at $2.7B and net profit margin improving to 10.03%. Recent news highlights institutional buying and positive analyst coverage, with 62.5% of analysts rating it a Buy.
Outlook remains positive due to earnings momentum and institutional interest, but risks include high valuation multiples and competitive pressures. The consensus price target is $57.80, slightly below current levels, suggesting near-term consolidation may occur. Investors should weigh growth prospects against elevated P/E and P/S ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
